IONIS PHARMACEUTICALS
Ionis Pharmaceuticals is a drugmaker company. Ionis Pharmaceuticals engages in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
IONIS PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
1989-01-01
Address:
Carlsbad, California, United States
Country:
United States
Website Url:
http://www.ionispharma.com
Total Employee:
251+
Status:
Active
Contact:
(760)931-9200
Total Funding:
751.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Sitelinks Search Box Euro Organization Schema IPv6
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Aerogen
Aerogen is a medical device and drug delivery company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Asieris Pharmaceuticals
Asieris Pharmaceuticals is a Chinese biotech company.
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
Kissei Pharmaceutical
Kissei Pharmaceutical is a food company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
SciClone Pharmaceuticals
SciClone Pharmaceuticals is a pharmaceutical company.
Xenon Pharmaceuticals
Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-08-31 | Akcea Therapeutics | Akcea Therapeutics acquired by Ionis Pharmaceuticals | 500 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-01-05 | Aro Biotherapeutics | Ionis Pharmaceuticals investment in Series A - Aro Biotherapeutics | 88 M USD |
| 2020-01-09 | Empirico | Ionis Pharmaceuticals investment in Series A - Empirico | 17 M USD |
| 2007-03-01 | Atlantic Healthcare | Ionis Pharmaceuticals investment in Seed Round - Atlantic Healthcare | 6.8 M USD |
Newest Events participated
Participated in TIDES: Oligonucleotide and Peptide Therapeutics 2017
on 2017-04-30 as exhibitor
Key Employee Changes
Official Site Inspections
http://www.ionispharma.com Semrush global rank: 1.45 M Semrush visits lastest month: 19 K
- Host name: 104.21.32.234
- IP address: 104.21.32.234
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ionis Pharmaceuticals"
Innovating to Change the Course of Human Health | IONIS
Nov 7, 2024 Our Science and Technology Rooted in a Deep Understanding of Genetics. The genetic basis of human disease continues to inspire our science and technology as we expand …See details»
Ionis Pharmaceuticals - Wikipedia
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (togethe…See details»
Ionis Pharmaceuticals - Crunchbase Company Profile & Funding
Phone Number (760)931-9200. Ionis Pharmaceuticals is a pharmaceutical company. It specializes in RNA-targeted drug discovery and development. Ionis has developed antisense technology, …See details»
Corporate Overview - ir.ionispharma.com
Company Overview Founded in 1989 in Carlsbad, CA to develop a new RNA-targeted drug discovery and development platform Pipeline of over 40 antisense medicines Three approved …See details»
Ionis Pharmaceuticals, Inc. | LinkedIn
Ionis Pharmaceuticals, Inc. Biotechnology Research Carlsbad, CA 70,386 followers Building on our impossible firsts, we can change the course of human health.See details»
Investors & Media | Ionis Pharmaceuticals, Inc.
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to …See details»
Ionis shares significant business and pipeline progress at …
Oct 4, 2023 We have matched this engine with a talented commercial organization poised to deliver a steady flow of wholly owned medicines to patients. With last week's announcement of …See details»
Ionis poised for continued momentum in 2024 with product …
Jan 8, 2024 To learn more about Ionis visit www.ionispharma.com and follow us on X (Twitter) @ionispharma and LinkedIn. Ionis' Forward-looking Statements This press release includes …See details»
FY 2022 Financial Results and Business Update - Ionis …
Www.ionispharma.com. In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and ... an integrated …See details»
Ionis Pharmaceuticals - Craft
Oct 29, 2024 Ionis Pharmaceuticals has 5 employees at their 1 location and $787.65 m in annual revenue in FY 2023. See insights on Ionis Pharmaceuticals including office locations, …See details»
Grants & Sponsorships: Medical & Research | IONIS
Please note that the recipient of the grant must be an appropriate organization such as a hospital, university, school of medicine, nursing, or pharmacy, a professional society or association, a …See details»
Ionis announces new chief global product strategy officer to lead …
Feb 29, 2024 Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another opportunity.To support the transition, Ms. Cadoret …See details»
Ionis shares significant business and pipeline progress at ... - Nasdaq
Oct 4, 2023 We have matched this engine with a talented commercial organization poised to deliver a steady flow of wholly owned medicines to patients. ... To learn more about Ionis visit …See details»
Ionis poised for continued momentum in 2024 with product …
Jan 8, 2024 Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2023 achievements and previewed a number of important milestones expected in …See details»
Release Details - ir.ionispharma.com
CARLSBAD, Calif., Jan. 19, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two appointments that strengthen its leadership team and further position it …See details»
Innovating to Change the Course of Human Health | IONIS
Ionis is continually advancing the design, screening, and development of its investigational RNA-targeted medicines to optimize the selection of investigational medicines for neurologic …See details»
Ionis poised for continued momentum in 2024 with product …
Jan 8, 2024 To learn more about Ionis visit www.ionispharma.com and follow us on X (Twitter) @ionispharma and LinkedIn. Ionis' Forward-looking Statements.See details»
Ionis reports third quarter financial results
Nov 9, 2022 "Our strong year-to-date results, including year-over-year revenue growth of nearly 20 percent, keep us on track to meet our 2022 P&L guidance," said Elizabeth L. Hougen, chief …See details»
Ionis announces new chief global product strategy officer to lead …
Feb 29, 2024 Ionis logo (PRNewsfoto/Ionis Pharmaceuticals, Inc.) Onaiza Cadoret-Manier, chief global product strategy and operations officer, is leaving the company to pursue another …See details»
Ionis reports third quarter 2021 financial results and recent …
Nov 3, 2021 To learn more about Ionis visit www.ionispharma.com or follow us on Twitter @ionispharma. Ionis' Forward-looking Statement This press release includes forward-looking …See details»